Sema4 Holdings Corp - Ordinary Shares - Class A Aktie News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and acquired shares on or before January 18, 2022, you may be able to seek corporate governance reforms, the return of funds back to the company,...

Earning an FDA Breakthrough Device Designation, GeneDx stock targets a breakout ahead of earnings — and expectations of 954% growth.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Showcases Leadership in gNBS at ICoNS 2025 with data from more than 22,000 newborns.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announces that the FDA has granted Breakthrough Device Designation for its whole genome and exome tests.

Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellatio...

GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gross margin, positive cash flow, and raised full-year guidance, signaling accelerating adoption. The AAP's new recommendations and NIH funding position WGS for significant market expansion, with insur...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx today announced its involvement in the Sunshine Genetics Act, establishing the nation's first state-backed genomic newborn screening program.